Allogene Therapeutics plans restructuring as it swaps out PhII CAR-T trial plans to leapfrog rivals
Allogene Therapeutics is switching up clinical plans for its off-the-shelf CAR-T therapies. In a bid to leapfrog more established rivals, the South San Francisco biotech will deprioritize two current Phase II trials of its lead candidate — its most advanced — and launch a new late-stage study with a much different design, it announced late Thursday.
As a result of the new approach, Allogene will also implement a “planned restructuring” this quarter to align with the smaller trial footprint and prioritized pipeline, the biotech said in a release. While it didn’t spell out specific implications, the move is expected to extend its runway from 2025 into 2026.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.